Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APSOctober 15, 2019CardiologyHematology
FDA adds diabetic kidney disease, heart failure indications to canagliflozinSeptember 30, 2019CardiologyEndocrinology
Heart disease raises risk of severe cutaneous adverse reactions to allopurinolSeptember 30, 2019CardiologyDermatology
Machine learning–derived risk score predicts heart failure risk in diabetes patientsSeptember 22, 2019CardiologyEndocrinology
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CADSeptember 1, 2019CardiologyNeurologyEndocrinology
